乙型肝炎肝硬化抗病毒治疗的进展

doi:10.3969/j.issn.1672-5069.2018.01.041

摘要/Abstract

摘要： 乙型肝炎病毒（Hepatitis B virus,HBV）感染呈世界性流行, 目前HBV慢性感染是导致肝硬化及肝癌的主要原因,也是全球重要的健康问题。乙型肝炎肝硬化的发生、疾病进展、预后情况与血清HBV DNA水平密切相关,且有多项研究表明有效抑制HBV复制可以改善甚至逆转肝纤维化,降低肝硬化患者长期并发症发生的概率,改善预后,降低肝硬化及肝癌的发生。因而有效地抗病毒治疗对肝硬化患者尤为重要。目前主要抗病毒治疗药物为干扰素类和核苷酸类药物,且近年来在安全性及方案选择方面有了较大的研究进展。

关键词: 肝硬化, 慢性乙型肝炎, 抗病毒治疗

Abstract: Hepatitis B virus （HBV） infection is popular worldwide. Chronic hepatitis B infection is the leading cause of liver cirrhosis and hepatocellular carcinoma, which is also one of the important public health problems. The occurrence of HBV-induced liver cirrhosis, disease progression, and prognosis are closely related to serum HBV DNA loads. Several studies have shown that effective inhibition of hepatitis B virus replication can improve, even reverse hepatic fibrosis, reduce the probability of long-term complications in patients with cirrhosis, improve prognosis and lower the occurrence of liver cirrhosis and hepatocellular carcinoma. Thus, effective antiviral treatments in patients with liver cirrhosis is particularly important. At present, the main antiviral agents are interferon-αand nucleos(t)ide analogues, and in recent years there are lots of progresses in terms of safety and scheme selection of them.

Key words: Liver cirrhosis, Hepatitis B, antiviral therapy

谢晓综述, 陆伦根审校. 乙型肝炎肝硬化抗病毒治疗的进展[J]. 实用肝脏病杂志, 2018, 21(1): 140-144.

Xie Xiao, Lu Lungen. Advances in antiviral treatments of HBV-induced liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 140-144.

参考文献

[1] Ott JJ, Stevens GA, Groeger J,et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30（12）: 2212-2219.
[2] Croagh CM,Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol,2014,20（30） 10395-10404.
[3] Lok AS. The maze of treatments for hepatitis B. N Engl J Med,2005,352（26）:2743-2746.
[4] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet, 2012, 380（9859）: 2095-2128.
[5] Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol,2005,34（6）:1329-1339.
[6] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China.Hepatology,2014,60（6）:2099-2108.
[7] Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol, 2013, 59（4）: 880-881.
[8] Li CZ, Cheng LF, Li QS, et a1. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol, 2013, 19（40）: 6849-6856.
[9] 科技部十二五重大专项联合课题组.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 实用肝脏病杂志,2014,17（2）：225-234.
[10] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130（3）: 678-686.
[11] Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology, 2011, 141（4）:1240-1248.
[12] Zhang QQ, An X, Liu YH, et al. Long-term nucleos（t）ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J, 2011, 8（2）:72.
[13] Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol,2010,52（2）:176-182.
[14] Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology, 2011, 54（1）:91-100.
[15] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006, 131（6）: 1743-1751.
[16] Marcellin P,Chang TT,Lim SG,et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology,2008,48（3）: 750-758.
[17] Chang TT,Liaw YF,Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010, 52（3）: 886-893.
[18] Schiff ER,Lee SS,Chao YC,et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol,2011,9（3）:274-276.
[19] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study. Lancet,2013,381（9865）: 468-475.
[20] Tang WB,Xu QH,Jiao ZY,et al. Effect of pressure on liver stiffness during the development of liver fibrosis in rabbits. Ultrasound Med Biol,2016,42（1）: 282-289.
[21] Osakabe K, Ichino N,Nishikawa T,et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol,2011,46（11）:1324-1334.
[22] Kuo YH, Lu SN, Chen CH,, et al. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One, 2014,9（3）:e93160.
[23] Seto WK, Fung J, Cheung KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B.Aliment Pharmacol Ther, 2016, 44（10）: 1071-1079.
[24] Song P, Feng X, Zhang K, et al. Screening for and surveillance of high-risk patients with HBV-related chronic.Biosci Trends, 2013, 7（1）:1-6.
[25] Fattovich G,Bortolotti F,Donato F. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors. J Hepatol,2008,48（2）:335-352.
[26] Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis:natural history and treatment.Semin Liver Dis, 2006, 26（2）:142-152.
[27] Lo GH. Does long-term entecavir treatment really reduce hepatocellular carcinoma incidence in patients with hepatitis B virus infection? Hepatology,2014, 59（5）:2053.
[28] Rapti IN,Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol,2011,5（3）:323-339.
[29] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 2015,64（12）:1972-1984.
[30] Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol,2005,42（5）:760-777.
[31] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,14（2）：81-89.
[32] European association for the study of the liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol, 2012, 57（1）: 167-185.
[33] Liaw YF,Kao JH,Piratvisuth T,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Hepatol Int,2012,6（3）:531-561.
[34] Terrault NA,Bzowej NH,Chang KM,et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2016,63（1）:261-283.
[35] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）.实用肝脏病杂志,2016,19（3）：389-400.
[36] Perrillo R,Tamburro C,Regenstein F,et al. Low-dose,titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology,1995,109（3）:908-916.